We examined expression of HA synthases (HAS1, HAS2, and HAS3) and hyaluronidases (HYAL1, HYAL2) in primary serous ovarian cancer cells isolated from patient ascites and CBP-resistant OV-90 cells. The gene discussed is HAS3; the disease is ovarian serous adenocarcinoma.